Evolus, Inc.

**SIGNAL NOTE: EcoR1 Capital initiates $4.5M position in Evolus (EOLS)** Growth-stage crossover investor EcoR1 Capital's entry into Evolus signals confidence in the aesthetic dermatology company's commercial trajectory, likely driven by increasing Jeuveau (prabotulinumtoxinA) market penetration in the competitive botulinum toxin space or anticipated label expansions. The $4.5M position (675K shares) suggests selective conviction rather than major portfolio commitment, positioning EcoR1 to benefit from potential inflection in market share or upcoming catalysts such as new indication data or margin expansion as the company scales manufacturing efficiency.